Although high CCL7 expression in colorectal (160, 161), breast (162), and uterine (163) cancer is known to promote metastasis and suppress tumor immunity, the expression of CCL7 in NSCLC has been shown to be anti-tumorigenic (164). Here, CCL7 is linked to neoplasm.